

EXHIBIT D

EXHIBIT D: THE PARTIES' JOINT AND SEPARATE EXHIBITS

Exhibit	Description	Offered By	Source	Production No.	Objection
TE100	Certified Copy of U.S. Patent No. 6,867,031	Novozymes and Genencor/EDC			Stipulated
TE101	Certified Copy of the File History for U.S. Patent No. 6,867,031	Novozymes and Genencor/EDC			Stipulated
TE102	"Structural Analysis of a Chimeric Bacterial -Amaylase. High-Resolution Analysis of Native and Ligand Complexes", Brzozowski, Andrej, David M. Lawson Biochemistry 2000, pp. 9009-9107	Novozymes	Gideon Davies Deposition Exhibit No. 100		Stipulated
TE103	Website pages entitled "An Information Portal to Biological Macromolecular Structures" www.rcsb.org	Novozymes	Gideon Davies Deposition Exhibit No. 101		Stipulated
TE104	Superposition of BLA domain B in the absence and presences of calcium, viewed from two separate vantage points	Novozymes	Gideon Davies Deposition Exhibit No. 105		Stipulate to use as a demonstrative. Reserve right to object under FRE 401-403 (Relevance) if offered as evidence.
TE105	Curriculum Vitae of Gideon J. Davies	Novozymes	Gideon Davies Deposition Exhibit No. 106		Stipulated
TE106	"The crystal structure of citrate synthase from the thermophilic Archaeon,	Novozymes and Genencor/EDC	Gideon Davies Deposition Exh.		Stipulated

{W:\037766003018000\00876715.DOC *037766003018000* }

- 1 -

MPI-40222v1

Exhibit	Description	Offered By	Source	Production No.	Objection
	Thermoplasma acidophilum” Rupert JM Russell, David W. Hugh, Michael J. Danson and Garry L. Taylor, (1994)		108; Exh. 2 to Second Arnold Declaration; Exh. Q to the Machius Expert Report; Exh. 7 to the Davies Rebuttal		
TE107	EBS ₂ -amylase Analytical Report	Novozymes	Frances Hamilton Arnold Deposition Exhibit No. 83	GCOR072633 - GCOR072642	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE108	“Rapid and Sensitive Protein Similarity Searches”, David J. Lipman and William R. Pearson, Science, March (1985)	Novozymes and Genencor/EDC	John Rickert Devereux Deposition Exh. No. 21; Devereux Deposition Exh. 21; Exh. 28 to the Second Alber Report; Exh. 2 to the Alber Declaration (APP. 162-170)		Stipulated
TE109	“A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins” Saul B. Needleman and Christian D. Wunsch, J.	Novozymes and Genencor/EDC	John Rickert Devereux Deposition Exh. No. 22; Devereux		Stipulated

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 2 -

MPI-4022v1

Exhibit	Description	Offered By	Source	Production No.	Objection
	Mol. Biol. (1970)		Deposition Exh. 22		
TE110	Email string dated 01/14/04 between Henrik-Bisgard-Frantzen and Jason Garbell regarding UltraphLo revisited	Novozymes	Jason Garbell Deposition Exhibit No. 65	NV-02000004 - NV-02000007	Stipulated subject to additional objections arising out of discovery on the "Waived Subjects"
TE111	Email string dated 02/25/04 between Torben Vedel Borchert and Jason Garbell regarding 4318 Divisionals	Novozymes	Jason Garbell Deposition Exhibit No. 66	NV-02000002 - NV-02000003	Stipulated subject to additional objections arising out of discovery on the "Waived Subjects"
TE112	Email string dated 06/08/04 between Carsten Andersen and Jason Garbell	Novozymes	Jason Garbell Deposition Exhibit No. 67	NV-02000001	Stipulated subject to additional objections arising out of discovery on the "Waived Subjects"
TE113	8871608.txt installation notes	Novozymes and Genencor/EDC	Pearson Deposition Exh. 71		Stipulated
TE114	Data that formed basis of the experiments described in Declaration of Torben V. Borchert under 37 C.F.R. 1.132 dated 09/06/04 Application No. 10/025,648	Novozymes and Genencor/EDC	Borchert Deposition Exh. 50; Exh. 7 to the Arnold Rebuttal Report; Exh. L to the Klibanov Report	NV-0174630 - NV-0174688	Stipulated
TE115	"Amino Acid Residues Stabilizing a	Novozymes and	Borchert		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
	Bacillus -Amylase against Irreversible Thermoinactivation", Suzuki et al., J. Biol. Chem., 1989, 264(32):18933-18938	Genencor/EDC	Deposition Exh. 52; Exh. H to Defendant's Opposition (APP. 980-985); Exh. 4 to the Second Arnold Declaration (APP. 843 - 848); Exh. 2 to Borchert Declaration; Exh. 4 to the Arnold Rebuttal Report; Exh. 8 to the Davies Rebuttal; Exh. S to the Machius Report; Exh. H to the Klibanov Report		
TE116	"Mechanisms of Irreversible Thermal Inactivation of Bacillus -Amylases", Tomazic and Klibanov, J. Biol. Chem., 1988, 263:3086-3091	Novozymes and Genencor/EDC	Exhibit 219 to the Deposition of Alexander Klibanov; Exh. 9 to the Davies Report; Exh. AC to the Alber Report; Exh. T to the Machius Report; Exh. F to the Klibanov Report		Stipulated

{W:\037766003018000\00876715.DOC *037766003018000* }

- 4 -

Exhibit	Description	Offered By	Source	Production No.	Objection
TE117	“Why is One Bacillus -amylase More Resistant against Irreversible Thermoinactivation Than Another”, Susan J. Tomzic and Alexander M. Kilbanov, .The Journal of Biological Chemistry, (1988) Susan J. Tomzic and Alexander M. Kilbanov, The Journal of Biological Chemistry, (1988), 263:3092-3096	Novozymes and Genencor/EDC	Exh. 220 to the Deposition of Alexander Kilbanov; Exh. AD to the Alber Report; Exh. G to the Kilbanov Report; Exh. 10 to the Davies Rebuttal; Exh. U to the Machius Expert Report		Stipulated
TE118	X-ray structure coordinates of the B. lichenformis alpha-amylase described in Machius '95, as downloaded from the Protein DataBank < http://www.pdb.org >, Accession No. 1BPL	Novozymes	Exhibit 12 to Davies Rebuttal Expert Report		Objection: FRE 401-403 (Relevance)
TE119	X-ray structure coordinates of the B. lichenformis alpha-amylase described in Machius '98, as downloaded from the Protein Data Bank < http://www.pdb.org >, Accession No. 1BLI	Novozymes	Exhibit 13 to Davies Rebuttal Expert Report		Objection: FRE 401-403 (Relevance)
TE120	Frances Hamilton Arnold Curriculum Vitae	Novozymes	Exhibit 1 to Frances Hamilton Arnold Expert Report		Stipulated
TE121	11/27/01 Document entitled “Production Culture History”	Novozymes	Exhibit 2 to Frances Hamilton Arnold Expert Report	GCOR003611	Stipulate to use as a demonstrative. Reserve right to

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 5 -

MPI-40222v1

Exhibit	Description	Offered By	Source	Production No.	Objection
					object under FRE 801-802 (Hearsay) if offered as evidence.
TE122	G-Zyme® G997 Alpha Amylase	Novozymes	Exhibit 4 to Frances Hamilton Arnold Expert Report	GCOR08935 - GCOR08936	Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE123	Sequence of G997	Novozymes	Exhibit 6 to Frances Hamilton Arnold Expert Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE124	Gap Alignment: G997 to Seq. ID No. 3	Novozymes	Exhibit 7 to Frances Hamilton Arnold Expert Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE125	Spezyme Ethyl® Amino Acid Sequence	Novozymes	Exhibit 9 to Frances Hamilton Arnold Expert Report		Stipulated
TE126	GAP Alignment: G997 to Spezyme Ethyl	Novozymes	Exhibit 10 to		Stipulate to use as a

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 6 -

Exhibit	Description	Offered By	Source	Production No.	Objection
			Frances Hamilton Arnold Expert Report		demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE127	GAP Alignment: Seq. ID No:3 to Spezyme Ethyl (Old Matrix)	Novozymes	Exhibit 11 to Frances Hamilton Arnold Expert Report		Stipulated
TE128	GAP Alignment: Sequence 3 (Figure 1) to Spezyme Ethyl (Old Matrix)	Novozymes	Exhibit 12 to Frances Hamilton Arnold Expert Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE129	Alpha Amylase Alignments	Novozymes	Exhibit 13 to Frances Hamilton Arnold Expert Report		Stipulated
TE130	Linear regression plots prepared by me for the experimental data set in the Borchert Declaration	Novozymes	Exhibit 9 to Frances Hamilton Arnold Rebuttal Expert Report		Stipulated
TE131	Curriculum Vitae of John Devereux	Novozymes	Exhibit 1 to John Devereux Expert Report		Stipulated
TE132	GAP Alignment: Seq ID No:3 to	Novozymes	Exhibit 4 to John		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
	Spezyme Ethyl (New Matrix)		Devereux Expert Report		
TE133	GAP Alignment: G997 to SEQ ID No:3	Novozymes	Exhibit 8 to John Devereux Expert Report		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE134	SPEZYME® ETHYL: High Performance Alpha-Amylase for Fuel Ethanol Processes	Novozymes	Exhibit 2 to Frances Hamilton Arnold Declaration in Support of Plaintiff's Motion for Preliminary Injunction		Stipulated
TE135	ATCC 31,195 Alpha-Amylase Amino Acid Sequence	Novozymes	Exhibit 4 to Frances Hamilton Arnold Declaration in Support of Plaintiff's Motion for Preliminary Injunction		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE136	GAP ALIGNMENT: ATCC 31,195 Alpha-Amylase to Spezyme Ethyl (Old Matrix)	Novozymes	Exhibit 5 to Frances Hamilton Arnold Declaration in Support of Plaintiff's Motion for Preliminary Injunction		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as

Exhibit	Description	Offered By	Source	Production No.	Objection
TE137	GAP ALIGNMENT: ATCC 31,195 Alpha-Amylase to Spezyme Ethyl (New Matrix)	Novozymes	Injunction Exhibit 6 to Frances Hamilton Arnold Declaration in Support of Plaintiff's Motion for Preliminary Injunction		evidence. Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE138	Webster's Ninth New Collegiate Dictionary (1991), pp. 855, 1304	Novozymes and Genencor/EDC	Exhibit E to Appendix to Memorandum of Law in Support of Plaintiff's Motion for a Preliminary Injunction		Stipulated
TE139	Spezyme Ethyl DNA Sequence	Novozymes	Exhibit 2 to Christian Isak Jørgensen Declaration in Support of Plaintiff's Motion for Preliminary Injunction and Exhibit 9 to Second Expert Report of Thomas C. Alber)		Stipulated
TE140	GenBank Accession No. AF032864	Novozymes	Exhibit 4 to Christian Isak Jørgensen		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
			Declaration in Support of Plaintiff's Motion for Preliminary Injunction		
TE141	GenBank Accession NO. AAB86961	Novozymes	Exhibit 5 to Christian Isak Jørgensen Declaration in Support of Plaintiff's Motion for Preliminary Injunction		Stipulated
TE142	"Cloning of a Chromosomal -amylase gene from <i>Bacillus stearothermophilus</i> ," Jørgensen et al., FEMS Microbiol. Let., 1991, 77:271-276	Novozymes and Genencor/EDC	Exh. 3 to the S. Jørgensen Declaration i/s/o Plaintiff's Motion for Preliminary Injunction; Exh. 18 to the Second Alber Report		Stipulated
TE143	Internal Genencor Correspondence ("Notice Documents")	Novozymes	Exhibit J to Novozymes Reply Brief in Support of Motion for a Preliminary Injunction	GCOR120413, GCOR120472, GCOR119962, GCOR119439 - 119440	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE144	Genencor Patent Application No 11/102,188 "Mutant -Amylase"	Novozymes	Exhibit R to Novozymes Reply	GCOR005142 - GCOR005196	Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
TE145	“Thermozymes: identifying molecular determinants of protein structural and functional stability”, Claire Vieille and J. Gregory Zeikus and Norman R. Pace, Tibtech, (1996)	Novozymes	Brief in Support of Motion for a Preliminary Injunction Exhibit 1 to Second Declaration of Frances Hamilton Arnold in support of Novozymes Reply Brief in Support of Motion for a Preliminary Injunction		Stipulate to use as a demonstrative. Reserve right to object under FRE 401-403 (Relevance) if offered as evidence.
TE146	The amino acid sequence of Spezyme ethyl	Novozymes	Exhibit 11 to the Second Declaration of Frances Hamilton Arnold in support of Novozymes Reply Brief in Support of Motion for a Preliminary Injunction		Stipulate to use as a demonstrative. Reserve right to object under FRE 401-403 (Relevance) if offered as evidence.
TE147	The amino acid sequence of the ATCC 39,709 (G997) enzyme	Novozymes	Exhibit 11 to Second Declaration of Frances Hamilton Arnold in support of Novozymes Reply		Stipulate to use as a demonstrative. Reserve right to object under FRE 401-403 (Relevance) if

{W:\037766003018000\00876715.DOC *037766003018000* }

- 11 -

Exhibit	Description	Offered By	Source	Production No.	Objection
			Brief in Support of Motion for a Preliminary Injunction		offered as evidence.
TE148	The alignment of the amino acid sequence of EBS2 (Spezyme ® Ethyl) and its parents (G997)	Novozymes	Exh. 12 to the Second Declaration of Frances Hamilton Arnold i/s/o Novozymes Reply Brief i/s/o Motion for Preliminary Injunction		Stipulate to use as a demonstrative. Reserve right to object under FRE 801-802 (Hearsay) if offered as evidence.
TE149	U.S. Patent Application No. 09/327,563 “-Amylase Mutants”	Novozymes	Exhibit 5 to Torben V. Borchert Declaration		Stipulated
TE150	Citation Search Reports	Novozymes	Exhibit FF to Novozymes Reply Brief in Support of Motion for a Preliminary Injunction		Objection: FRE 401-403 (Relevance)
TE151	Spezyme Ethyl Amylase Presentation	Novozymes	Exhibit 6 to Declaration of David J. Teece in support of Genencor's and EDC's Appendix in Opposition to	GCOR011312 - GCOR011401	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)

Exhibit	Description	Offered By	Source	Production No.	Objection
			Novozymes' Motion for Preliminary Injunction		
TE152	Winning against Spezyme Ethyl Strategy	Novozymes and Genencor/EDC	Exh. 23 to Teece Declaration i/s/o Genencor and EDC's Appendix in Opposition to Novozymes' Motion for Preliminary (APP. 2246 - 2252)	NV-0004747 - NV-0004753	Stipulated
TE153	12/16/03 & 12/17/03 Emails between Eugenio Ferrari, Beth Concoby and Cees Broekhuizen regarding tier 1 documents	Novozymes	W. Douglas Crabb Deposition Exhibit No. 3	GCOR079654 - GCOR079655	Objection: FRE 801-802 (Hearsay)
TE154	Eugenio Ferrari file titled "ETHYL"	Novozymes	W. Douglas Crabb Deposition Exhibit No. 4	GCOR003607 - GCOR003615	Objection: FRE 801-802 (Hearsay)
TE155	12/16/03, 12/17/03 & 12/20/03 Emails between Doug Crabb, Eugenio Ferrari, Beth Concoby and Cees Broekhuizen regarding tier 1 documents	Novozymes	W. Douglas Crabb Deposition Exhibit No. 5	GCOR079821 - GCOR079823	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE156	Document titled "EBS-2 product development input - Grain Processing BIT discussion - August 13, 2003	Novozymes	W. Douglas Crabb Deposition Exhibit No. 6)	GCOR002598 - GCOR002609	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 13 -

MPI-4022v1

Exhibit	Description	Offered By	Source	Production No.	Objection
TE157	10/29/02 & 10/30/02 Emails between Kevin Griffith, Doug Crabb, Jodi Henderson and John Gell regarding Non IP Issue Ultra-pHLo	Novozymes	W. Douglas Crabb Deposition Exhibit No. 8	GCOR136592 - GCOR136593	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE158	04/05/05 Judy Chang Report titled "Analytical Characterization of EBS2	Novozymes	W. Douglas Crabb Deposition Exhibit No. 9	GCOR003358 - GCOR003376	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE159	04/16/03 Email from Doug Crabb to Tom Anderton and Eugenio Ferrari regarding Alignment for EBS2	Novozymes	W. Douglas Crabb Deposition Exhibit No. 10	GCOR079790	Objection: FRE 801-802 (Hearsay)
TE160	06/27/05 Document titled "Sequences and Sources for EBS wt and B.stearthermophilus genes and engineered variants"	Novozymes	W. Douglas Crabb Deposition Exhibit No. 11	GCOR032513	Objection: FRE 801-802 (Hearsay)
TE161	04/19/04 Judy Chang Report titled "EBS2 -amylase Analytical Report - Analytical Characterization of EBS2 molecule"	Novozymes	W. Douglas Crabb Deposition Exhibit No. 12; Thomas C. Alber Deposition Exhibit No. 203; Frances Hamilton Arnold Deposition Exhibit No. 83	GCOR072633 - GCOR072642	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE162	Genencor presentation titled "pH 4 - Amylase - Goal: A single pH liquefaction and saccharification process for hydrolyzing starch"	Novozymes	W. Douglas Crabb Deposition Exhibit No. 13	GCOR037149 - GCOR037161	Objection: FRE 401-403 (Relevance) FRE 801-802

Exhibit	Description	Offered By	Source	Production No.	Objection
					(Hearsay)
TE163	08/18/03 Michelle J. Vernier Presentation titled "EBS2/Fred Upgrade, Alpha Amylase Update"	Novozymes	W. Douglas Crabb Deposition Exhibit No. 14	GCOR032614 - GCOR032639	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE164	03/08/04 Emails between Doug Crabb, Eugenio Ferrari and Cynthia Blumenthal regarding EBS2	Novozymes	W. Douglas Crabb Deposition Exhibit No. 15	GCOR072543 - GCOR072545	Objection: FRE 801-802 (Hearsay)
TE165	04/19/02 & 04/22/02 Emails between Doug Crabb, Kevin Griffith and Jodi Henderson regarding EBS's Proposed New Ultra-pHLo Product	Novozymes	W. Douglas Crabb Deposition Exhibit No. 16	GCOR071139 - GCOR071140	Objection: FRE 801-802 (Hearsay)
TE166	10/10/02 Email from Doug Crabb to John Gell, John Monks and Volkert Claassen regarding Fred Upgrade Update	Novozymes	W. Douglas Crabb Deposition Exhibit No. 17	GCOR112536 - GCOR112538	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE167	07/07/05 Email from Tom Alber to Brett Lovejoy regarding Genencor	Novozymes	Thomas Alber Deposition Exhibit No. 102	GCOR167130 - GCOR167132	Stipulated
TE168	Hand drawing of two sequences of amino acids labeled "A" and "B" with 10 amino acids in a row deleted from the middle of "B"	Novozymes	Thomas Alber Deposition Exhibit No. 103		Stipulated
TE169	Handwritten notes of Thomas Alber made when drafting his declaration	Novozymes	Thomas Alber Deposition Exhibit No. 105	GCOR166891 - GCOR166892	Stipulated
TE170	08/08/05 Email from Brett Lovejoy to	Novozymes	Thomas Alber	GCOR166926 -	Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
	tom@ucxray.berkeley.edu attaching file titled "CAJD 514823.DOC"		Deposition Exhibit No. 107	GCOR166928	
TE171	Handwritten notes of Thomas Alber describing edits to a late version of his declaration	Novozymes	Thomas Alber Deposition Exhibit No. 109	GCOR166897 - GCOR166901	Stipulated
TE172	Genencor Presentation titled "Spezyme® Ethyl/Prime Amylase"	Novozymes	David J. Teece Deposition Exhibit No. 5	GCOR112335 - GCOR112408	Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE173	"Crystal Structure of Calcium-depleted Bacillus licheniformis -amylase at 2.2 Å Resolution", Machius et al., J. Mol. Biol., 1995, 246:545-559	Novozymes and Genencor/EDC	Zeikus Deposition Exh. 153; Machius Deposition Exh. 212 (in color without bates no.; S. Jorgensen Deposition Exh. 12); S. Jorgensen Deposition Exh. 12; Exh. 6 to the Second Arnold Declaration; Exh. 1 to Borchert Declaration; Borchert Deposition Exh. 57; Exh. H to Defendant's Opposition (APP.		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
			1304-1332); Exh. Z to the Alber Report; Exh. M to the Machius Expert Report; Exh. 3 to the Arnold Rebuttal Report; Exh. 5 to the Davies Rebuttal		
TE174	09/07/05 Email from Greg Zeikus to Muna Abu-Shaar attaching re-plotted Borchert data	Novozymes	Gregory Zeikus Deposition Exhibit No. 155	GCOR168937 - GCOR168938	Stipulated
TE175	“Activation of Bacillus licheniformis - amylase through a disorder→order transition of the substrate-binding site mediated by a calcium-sodium-calcium metal triad”, Machius et al., Structure, 1998, 6(3):281-292	Novozymes and Genencor/EDC	Zeikus Deposition Exh. 159; Exh. N to the Machius Expert Report; Exh. 6 to the Davies Rebuttal	GCOR168808 - GCOR168819	Stipulated
TE176	09/02/05 Email from Gregory Zeikus to Muna Abu Shaar attaching alfa amylase half-lives table	Novozymes	Gregory Zeikus Deposition Exhibit No. 161	GCOR168950 - GCOR168951	Stipulated
TE177	Bisgard-Frantzen et al., International Patent Publication No. WO 95/10603	Novozymes and Genencor/EDC	Mischa Machius Deposition Exhibit No. 205		Stipulated
TE178	“Thermozymes: identifying molecular determinants of protein structural and functional stability”, Vieille and Zeikus, Trends in Biotechnology, 1996, 14:183-190	Novozymes and Genencor/EDC	Machius Deposition Exh. 206; Exh. V to the Machius Expert Report; Exh. 11 to the Davies Rebuttal; Exh. 1 to		Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
TE179	“The Structure of a Thermally Stable 3-Phosphoglycerate Kinase and a Comparison With Its Mesophilic Equivalent”, Davies et al., Proteins: Structure, Function, and Genetics, 1993, 15:283-289	Novozymes and Genencor/EDC	the Second Arnold Declaration (APP. 865-872) Mischa Machius Deposition Exhibit No. 208; Exh. 3 to the Second Arnold Declaration (APP. 772-779); Exh. 4 to the Davies Rebuttal; Exh. H to the Machius Expert Report		Stipulated
TE180	Certified Copy of English Translation of the thesis of Mischa Machius titled “Studies on the Structure/Function Relationships of Glutathione S-Transferases and -Amylases”	Novozymes	Mischa Machius Deposition Exhibit No. 209		Stipulated
TE181	“Complete Nucleotide Sequence of a Gene Coding for Heat- and pH-Stable -Amylase of Bacillus licheniformis: Comparison of the Amino Acid Sequences of Three Bacterial Liquefying -Amylases Deduced from the DNA Sequences”, Yuuki et al., J. Biochem, 1985, 98(5):1147-56	Novozymes and Genencor/EDC	Mischa Machius Deposition Exhibit No. 211; Exh. Z to the Machius Expert Report		Stipulated
TE182	Borchert Experimental Data (in color)	Novozymes and Genencor/EDC		NV200266	Stipulated
TE183	“Probing Structural Determinants	Novozymes and	Machius Deposition		Stipulated

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 18 -

MPL-40222v1

Exhibit	Description	Offered By	Source	Production No.	Objection
	Specifying High Thermostability in Bacillus licheniformis -Amylase", Declerck et al., J. Mol. Biol., 2000, 301:1041-1057	Genencor/EDC	Exh. 213; Exh. AO to the Alber Report		
TE184	"Hyperthermostabilization of Bacillus licheniformis -amylase and modulation of its stability over a 50°C temperature range", Declerck et al., Protein Engineering, 2003, 16(4):287-293	Novozymes and Genencor/EDC	Machius Deposition Exh. 215; Exh. AM to the Alber Report; Exh. J to the Machius Expert Report		Stipulated
TE185	"Hyperthermostable Variants of a Highly Thermostable Alpha-Amylase", Joyet et al., Biotechnology, 1992, 10(12):1579-1583	Novozymes and Genencor/EDC	Machius Deposition Exh. 216; Exh. K to the Machius Expert Report		Stipulated
TE186	"Kinetic Stabilization of Bacillus licheniformis -Amylase through Introduction of Hydrophobic Residues at the Surface", Machius et al., The Journal of Biological Chemistry, 2003, 278(13):11546-11553	Novozymes and Genencor/EDC	Machius Deposition Exh. 217; Exh. AN to the Alber Report		Stipulated
TE187	Figure 1, an overall view of BLA in the absence of calcium	Novozymes and Genencor/EDC	Exh. D to the Machius Expert Report		Stipulated
TE188	Enzyme Development Corporation's Responses to Plaintiff Novozymes A/S' First Set of Interrogatories dated 07/22/05	Novozymes			Stipulated
TE189	Genencor International, Inc.'s Responses to Plaintiff Novozymes A/S' First Set of	Novozymes			Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
	Interrogatories dated 07/22/05				
TE190	Defendants' Responses to Plaintiff's First Set of Requests for Admissions dated 07/22/05	Novozymes			Stipulated
TE191	08/09/05 E-mail from Greg Lanier to Robert Sullivan Containing Supplemental Discovery Responses from Genencor and EDC	Novozymes			Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay)
TE192	Enzyme Development Corporation's Supplemental Responses to Plaintiff Novozymes A/S' First Set of Interrogatories dated 09/16/05	Novozymes			Stipulated
TE193	Genencor International, Inc.'s Second Supplemental Responses to Plaintiff Novozymes A/S' First Set of Interrogatories dated 01/09/06	Novozymes			Stipulated
TE194	Genencor International, Inc.'s Third Supplemental Responses to Plaintiff Novozymes A/S' First Set of Interrogatories dated 01/20/06	Novozymes			Stipulated
TE195	01/29/02 Memorandum from W. M. Teague to M. Friesema regarding The December 20 alpha-Amylase Mutant Methods of Construction	Novozymes	Exhibit 2 to the Declaration of W. Douglas Crabb in Support of Genencor's and EDC's Opposition to Novozymes' Motion for	GCOR002762 - GCOR002764	Stipulated

Exhibit	Description	Offered By	Source	Production No.	Objection
			Preliminary Injunction		
TE196	Spezyme Ethyl Sales Data	Novozymes		GCOR170228 - GCOR170232	Objection: FRE 401-403 (Relevance)
TE197	Spezyme Fred Sales Data	Novozymes		GCOR170228 - GCOR170232	Objection: FRE 401-403 (Relevance)
TE198	Genencor's [1st] Supplemental Response to Novozymes' First Set of Interrogatories dated 9/16/05	Novozymes			Stipulated
TE199	G-ZYME® G997 Amino Acid Sequence	Novozymes	Exhibit 2 to the Second Declaration of Christian Isak Jorgensen dated 12/19/05		Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay) FRCP 26/Court's Scheduling Orders
TE200	Genencor International Inc.'s Fourth Supplemental Response to Novozymes' First Set of Interrogatories dated January 31, 2006r	Novozymes			Stipulated
TE201	Amino Acid Sequence of Alpha-Amylase Isolated From BSG Strain ATCC 31,195	Novozymes	Exhibit 3 to the Third Declaration of Isak Jorgensen dated 1/31/06		Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay) FRCP 26/Court's Scheduling Orders

Exhibit	Description	Offered By	Source	Production No.	Objection
TE202	United States Patent Applicatio, Pub No. 2006/0014265 A1, titled "Mutant Alpha-Amylases", Ferrari et al.	Novozymes			Stipulated
TE203	File History for Patent Application 11/102,188	Novozymes		GCOR005142 - GCOR005196; GCOR170233 - GCOR170275	Stipulated
TE204	Enzyme Development Corporation's Second Supplemental Responses to Plaintiff Novozymes A/S' First Set of Interrogatories dated 1/31/06	Novozymes			Stipulated
TE205	ATCC 31,195 Experimental Protocol	Novozymes			Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay) FRCP 26/Court's Scheduling Orders
TE206	G997 Experimental Protocol	Novozymes			Objection: FRE 401-403 (Relevance) FRE 801-802 (Hearsay) FRCP 26/Court's Scheduling Orders
TE207	Pullulanase Activity/Stability Assay	Novozymes		NV200265	Objection: FRE 401-403 (Relevance) FRE 801-802

Exhibit	Description	Offered By	Source	Production No.	Objection (Hearsay) FRCP 26/Court's Scheduling Orders
TE208	Frances Arnold Linear Regression Plots	Novozymes		NV200267- NV200270	
TE209	Christian Jorgensen's ATCC 31,195 Database Entry	Novozymes		NV200281	
TE210	ATCC 31,195 Database Entry	Novozymes		NV200282	
TE211	Christian Jorgensen's G997 Database Entry	Novozymes		NV200283	
TE212	G997 Competitive Database Entry	Novozymes		NV200284	
TE213	France Arnold Linear Regression Plots (Ice-Zero Data)	Novozymes		NV200285- NV200287	
TE214	PHYSICAL EXHIBIT: Sample Novozymes vials used to hold BSG-DEL enzyme sample in the heat incubator/oven during the experiments of Borchert's 132 Declaration	Novozymes			
TE215	PHYSICAL EXHIBIT: Sample Novozymes test tubes used to hold enzyme samples in the PCR thermocycler	Novozymes			
TE216	PHYSICAL EXHIBIT: Standard eppendorf tubes that are used to hold enzyme sample during the amylase activity assay described in Dr. Borchert's 132 Declaration	Novozymes			
TE217	PHYSICAL EXHIBIT: Phadebas amylase test tablets used as substrate	Novozymes			

Exhibit	Description	Offered By	Source	Production No.	Objection
	during the amylase activity assay described in Dr. Borchert's 132 Declaration				
TE218	Jeppe Tams Lab Notebook 13704, pages 070-072 (re: Determination of ½ life for BAN-WT experiment)	Novozymes	Exhibit 113 to Deposition of Jeppe Tams	NV200203-NV200205	
TE219	Jeppe Tams Lab Notebook 15305, pages 044-046 (re: Determination of ½ life for BAN-WT experiment)	Novozymes	Exhibit 114 to Deposition of Jeppe Tams	NV200200-NV200202	
TE220	Defendants' English Language Translation of TE207 (Pullulanase Activity/Stability Assay)	Novozymes	Exhibit 307 to Deposition of Frances Arnold (2/28/06)		

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
227	NZ	2/16/05	Email attaching Ethyl Impact Analysis	NV-0028647 to NV-0028677	LeFebvre Deposition Exhibit No. 38	F.R.E. 801-802
228	NZ	9/13/05	Declaration of W. Douglas Crabb		Crabb Deposition Exhibit No. 1	Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
229	NZ	12/16/03 to 12/20/03	Genencor Email String, Subject: Tier 1 document	GCOR-079281 to GCOR-079823	Crabb Deposition Exhibit No. 5	Stipulated
230	NZ	8/13/03	EBS-2 Product Development Input -- Grain Processing BIT Discussion	GCOR-002598 to GCOR-002609	Crabb Deposition Exhibit No. 6	Stipulated
231	NZ	9/13/01	Letter from Steve Carlisle (Common Biotechnologies, Inc.) to Phillip Brumm (EBS) enclosing development package	GCOR-002919 to GCOR-002962	Crabb Deposition Exhibit No. 7	Stipulated
232	NZ	10/29/02 to 10/30	Genencor Email String, Subject: Non IP Issue Ultra-pHLo	GCOR-136592 to GCOR-136593	Crabb Deposition Exhibit No. 8	Stipulated
233	NZ	4/16/03	Genencor Email, Subject: Alignment for EBS2	GCOR-079790	Crabb Deposition Exhibit No. 10	Stipulated
234	NZ	6/27/05	Sequences and Sources for EBS wt B. stealthermophilus genes and engineered variants	GCOR-032513	Crabb Deposition Exhibit No. 11	Stipulated
235	NZ	8/18/03	EBS2/Fred Upgrade Alpha Amylase Update	GCOR-032614 to GCOR-032639	Crabb Deposition Exhibit No. 14	Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
236	NZ	3/8/04	Genecor Email String, Subject: EBS2	GCOR-072543 to GCOR-072545	Crabb Deposition Exhibit No. 15	Stipulated
237	NZ	4/19/02 to 4/22/02	Genecor Email String, Subject: EBS's Proposed New Ultra-pHLo Product	GCOR-071139 to GCOR-071140	Crabb Deposition Exhibit No. 16	Stipulated
238	NZ	10/10/02	Genecor Email String, Subject: Fred Upgrade Update	GCOR-112536 to GCOR-112538	Crabb Deposition Exhibit No. 17	Stipulated
239	NZ/GCOR		Annual NZAS/NZNA Charge Back Summary Chart	NV-D-0174787	Olofson Deposition Exhibit No. 504	Stipulated
240	NZ/GCOR	1/1/96	NZAS/NZNA Technology License Agreement with Amendment	NV-D-0174019 to NV-D-0174024	Olofson Deposition Exhibit No. 506	Stipulated
241	NZ/GCOR	1/1/05	NZAS/NZNA Marketing Agreement	NV-D-0174037 to NV-D-0174040	Olofson Deposition Exhibit No. 507	Stipulated
242	NZ/GCOR	1/1/01	NZAS/NZNA Framework Agreement For Service with Appendix	NV-D-0174025 to NV-D-0174031	Olofson Deposition Exhibit No. 508	Stipulated

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 26 -

MPI-40222v1

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
243	NZ/GCOR	12/22/04	NZAS/NZNA Service Agreement	NV-D-0174766 to NV-D-0174769	Olofson Deposition Exhibit No. 510	Stipulated
244	NZ	9/14/05	Declaration of David J. Teece		Teece Deposition Exhibit No. 1	Stipulated
245	NZ	9/13/05	Declaration of Phillip B. Nelson			Stipulated
246	NZ	9/13/05	Declaration of Maurice G. Beto			Stipulated
247	NZ	7/21/06	CV of Julie L. Davis, CPA		Davis Expert Report Exhibit No. 1	Stipulated
248	NZ	7/21/06	Index of Documents Considered by Julie L. Davis		Davis Expert Report Exhibit No. 2	Stipulated
249	NZ	7/21/06	Calculation of Lost Profits and Reasonable Royalty Damages		Davis Expert Report Exhibit No. 4A	F.R.E. 401-402, 702, 801-802

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
250	NZ	7/21/06	Calculation of Prejudgment Interest on Lost Profits and Reasonable Royalty Damages		Davis Expert Report Exhibit No. 4A1	F.R.E. 401-402, 702, 801-802
251	NZ	7/21/06	Summary of Lost Profits Calculation		Davis Expert Report Exhibit No. 4B	F.R.E. 401-402, 702, 801-802
252	NZ	7/21/06	2005 Lost Profits Calculation		Davis Expert Report Exhibit No. 4B1	F.R.E. 401-402, 702, 801-802
253	NZ	7/21/06	2006 Lost Profits Calculation		Davis Expert Report Exhibit No. 4B2	F.R.E. 401-402, 702, 801-802
254	NZ	7/21/06	Reasonable Royalty Calculation assuming Lost Profits		Davis Expert Report Exhibit No. 4C	F.R.E. 401-402, 702, 801-802
255	NZ	7/21/06	Sales Included in Reasonable Royalty Damages 2005		Davis Expert Report Exhibit No. 4C1	F.R.E. 401-402, 702, 801-802
256	NZ	7/21/06	Sales Included in Reasonable Royalty Damages 2006		Davis Expert Report Exhibit No. 4C2	F.R.E. 401-402, 702, 801-802

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 28 -

MPI-40222v1

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
257	NZ	7/21/06	Calculation of Price Erosion Damages		Davis Expert Report Exhibit No. 5A	F.R.E. 401-402, 702, 801-802
258	NZ	7/21/06	Calculation of Prejudgment Interest on Price Erosion Damages		Davis Expert Report Exhibit No. 5A1	F.R.E. 401-402, 702, 801-802
259	NZ	7/21/06	Calculation of Price Erosion Damages on Novozymes' Products		Davis Expert Report Exhibit No. 5B	F.R.E. 401-402, 702, 801-802
260	NZ	7/21/06	Calculation of Price Erosion Damages on Novozymes' Products by Month		Davis Expert Report Exhibit No. 5C	F.R.E. 401-402, 702, 801-802
260A	NZ	7/21/06	Novozymes' Quantity Sold by Product		Davis Expert Report Exhibit No. 5D	F.R.E. 401-402, 702, 801-802
261	NZ	7/21/06	Difference in Average Selling Price Per Month		Davis Expert Report Exhibit No. 5E	F.R.E. 401-402, 702, 801-802
262	NZ	7/21/06	Novozymes' Average Selling Price Per Product		Davis Expert Report Exhibit No. 5F	F.R.E. 401-402, 702, 801-802

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
263	NZ	7/21/06	Prime Interest Rates		Davis Expert Report Exhibit No. 6	F.R.E. 702, 801-802
264	NZ	7/21/06	Graph of Spezyme Ethyl, Spezyme Fred, and Liquezyme Products Quantity Sold into the Fuel Ethanol Industry		Davis Expert Report Exhibit No. 7A	F.R.E. 401-402, 702, 801-802
265	NZ	7/21/06	Graph of Spezyme Ethyl, Spezyme Fred, and Liquezyme Products Dollar Sold into the Fuel Ethanol Industry		Davis Expert Report Exhibit No. 7B	F.R.E. 401-402, 702, 801-802
266	NZ	7/21/06	Graph of Average Selling Prices of Liquezyme SC and Spezyme Ethyl		Davis Expert Report Exhibit No. 7C	F.R.E. 401-402, 702, 801-802
267	NZ	7/21/06	Data for Graphs A and B: Sales by Month of Spezyme Fred, Spezyme Ethyl, and Liquezyme Products 2003		Davis Expert Report Exhibit No. 7A1	F.R.E. 401-402, 702, 801-802
268	NZ	7/21/06	Data for Graphs A and B: Sales by Month of Spezyme Fred, Spezyme Ethyl, and Liquezyme Products 2004		Davis Expert Report Exhibit No. 7A2	F.R.E. 401-402, 702, 801-802
269	NZ	7/21/06	Data for Graphs A and B: Sales by Month of Spezyme Fred, Spezyme Ethyl, and Liquezyme Products 2005		Davis Expert Report Exhibit No. 7A3	F.R.E. 401-402, 702, 801-802

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 30 -

MPI-40222v1

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
270	NZ	7/21/06	Data for Graphs A and B: Sales by Month of Spezyme Fred, Spezyme Ethyl, and Liquezyme Products 2006		Davis Expert Report Exhibit No. 7A4	F.R.E. 401-402, 702, 801-802
271	NZ	7/21/06	Data for Graph C: Average Selling Price of Liquezyme SC and Spezyme Ethyl 2004		Davis Expert Report Exhibit No. 7B1	F.R.E. 401-402, 702, 801-802
272	NZ	7/21/06	Data for Graph C: Average Selling Price of Liquezyme SC and Spezyme Ethyl 2005		Davis Expert Report Exhibit No. 7B2	F.R.E. 401-402, 702, 801-802
273	NZ	7/21/06	Data for Graph C: Average Selling Price of Liquezyme SC and Spezyme Ethyl 2006		Davis Expert Report Exhibit No. 7B3	F.R.E. 401-402, 702, 801-802
274	NZ	7/21/06	Genencor Products Manufactured or Sold in the U.S. Summary		Davis Expert Report Appendix A	F.R.E. 401-402, 702, 801-802
275	NZ	7/21/06	Genencor Products Manufactured or Sold in the U.S. 2004 Detail by Month		Davis Expert Report Appendix A1	F.R.E. 401-402, 702, 801-802
276	NZ	7/21/06	Genencor Products Manufactured or Sold in the U.S. 2005 Detail by Month		Davis Expert Report Appendix A2	F.R.E. 401-402, 702, 801-802

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 31 -

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
277	NZ	7/21/06	Genencor Products Manufactured or Sold in the U.S. 2006 Details by Month		Davis Expert Report Appendix A3	F.R.E. 401-402, 702, 801-802
278	NZ	7/21/06	Genencor Alpha-Amylase Sales Manufactured or Sold in the U.S. by Industry		Davis Expert Report Appendix B	F.R.E. 401-402, 702, 801-802
279	NZ	7/21/06	Genencor Alpha-Amylase Sales Manufactured or Sold in the U.S. by Industry 2004		Davis Expert Report Appendix B1	F.R.E. 401-402, 702, 801-802
280	NZ	7/21/06	Genencor Alpha-Amylase Sales Manufactured or Sold in the U.S. by Industry 2005		Davis Expert Report Appendix B2	F.R.E. 401-402, 702, 801-802
281	NZ	7/21/06	Genencor Alpha-Amylase Sales Manufactured or Sold in the U.S. by Industry 2006		Davis Expert Report Appendix B3	F.R.E. 401-402, 702, 801-802
282	NZ	2/6/02	USPTO Notice of Recordation of Assignment Document			Stipulated
283	NZ	3/13/02	USPTO Notice of Recordation of Assignment Document			Stipulated

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 32 -

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
284	NZ	1/30/05	NZ Email, Subject: Ryan Heuer would like to inform you: For Your Info:	NV-D-0006483		F.R.E. 401-402, 801-802
285	NZ	1/26/02	Quest License Agreement	NV-D-0175437 to NV-D-0175442	Exh. 6 to the Julie L. Davis Deposition	Stipulated
286	NZ	1/25/05 to 1/26/05	NZ Email, Subject: Consignment Discussion with Finance	NV-D-0006515 to NV-D- 0006516		F.R.E. 801-802
287	NZ	1/13/06 to 2/28/06	NZ Email, Subject: Spezyme Ethyl	NV-D-0002267 to NV-D- 0002272		F.R.E. 801-802
288	NZ	10/4/05	UBS Report: Novozymes A/S	GCOR-474904 to GCOR-474925		F.R.E. 801-802
289	NZ	1/30/06	NZ Email, Subject: Idea: 32-5 - Help Create barrier to entry of GCI's RSH technology at ICM	NV-D-0006485 to NV-D- 0006486		F.R.E. 801-802
290	NZ	10/28/05	Genencor Email, Subject: SPEZYME ETHYL/Liquozyme SC Comparison	GCOR-475013		Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
291	NZ		Comparison of SPEZYME® ETHYL and Liquozyme® SC	EDC-025574 to EDC-025575		Stipulated
292	NZ	1/20/06	EDC Call Report: Front Range Energy	EDC-027799 to EDC-027800		Stipulated
293	NZ	6/12/06	Genencor Email, Subject: RPMG	GCOR-390569 to GCOR-390570		Stipulated
294	NZ	7/7/05	NZ Call Visit Reports for Termanyl, Liquizyme or Spezyme	NV-0076373 to NV-0076378		F.R.E. 801-802
295	NZ/GCOR	8/12/05	Genencor Monthly Report June/July 2005	GCOR-446122 to GCOR-446124		Stipulated
296	NZ/GCOR		EDC Call Report: Spezyme XTRA	EDC-025862		Stipulated
297	NZ		BioProducts Program Management Monthly Report April 2005	GCOR-448757 to GCOR-448764		Stipulated
298	NZ	12/14/05 to 12/16/05	Genencor Email, Subject: AA Document, attaching Ethyl Replacement Analysis Memo	GCOR-474963 to GCOR-474972		Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
299	NZ	3/23/06	EDC Email, Subject: DRAFT - Alpha Outlook	EDC-031782		Stipulated
300	NZ	3/25/06	EDC Email, Subject: an ad for HPA	EDC-031769		Stipulated
301	NZ	4/19/06	Genencor Email, Subject: GC 100 Supply transition plan	GCOR-389871		Stipulated
302	NZ	5/4/06 to 5/13/06	Genencor Email, Subject Spezyme Case, attaching GC 100 Trial Summary	GCOR-456377 to GCOR-456382		Stipulated
303	NZ	10/5/05	Genencor Email, Subject: hybrid amylase	GCOR-388041 to GCOR-388054		Stipulated
304	NZ	1/31/06	Genencor Email, Subject: Ethyl Backup Prelim. Plan, attaching plan	GCOR-388722 to GCOR-388723		Stipulated
305	NZ	4/3/06	EDC Email, Subject: GC 100 Alpha Amylase	EDC-031734		Stipulated
306	NZ	5/1/06	EDC April Progress Report	EDC-029851		Stipulated

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
307	NZ	5/15/06 to 5/23/06	Genencor Email, Subject: GC 100 Trial Summary, attaching GC 100 Trial Summary	GCOR-390429		Stipulated
308	NZ	5/26/06	Genencor Email, Subject: Ethyl replacement	GCOR-466225		Stipulated
309	NZ	5/24/06	FUNCTIONAL GROUP MEETING	EDC-027812		Stipulated
310	NZ	6/6/06	EDC Call Report: Golden Grain Energy - - GC 100 Trial	EDC-026988		Stipulated
311	NZ	6/15/06	Genencor Email, Subject: Denco GC 100 results	GCOR-473870		Stipulated
312	NZ	7/11/05 to 7/13/05	Genencor Email, Subject: Diversa/Valley Research Ultra-Thin pH4.5 AA	GCOR-455612 to GCOR-455613		Stipulated
313	NZ	12/14/05 to 12/16/05	Genencor Email, Subject: AA Document	GCOR-474963 to GCOR-474964		Stipulated
314	NZ/GCOR	4/17/06 to 4/18/06	Genencor Email, Subject: alpha amylase comparison	GCOR-389855 to GCOR- 389857		Stipulated

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 36 -

MPI-4022v1

T.E. #.	OFFERED BY	DATE	DESCRIPTION	PRODUCTION No.	SOURCE(S)	OBJECTION(S)
315	NZ	5/9/06	EDC Call Report: US Energy Partners	EDC-030822		Stipulated
316	NZ	5/17/06 to 6/2/06	Genencor Email: Repeat Items for GCOR BoD Meetings	GCOR-387661 to GCOR-387663		Stipulated
317	NZ		Applications Review: GP Group Meeting - September 10/11 2003, Beloit	GCOR-173223 to GCOR-173267		Stipulated
318	NZ	9/11/03	EDC Call Report: Genencor	EDC- 029831 to EDC- 029833		Stipulated
319	NZ	1/28/04 to 1/29/04	Genencor Email, Subject: Profitability Project Update - Draft Presentation for SMT	GCOR-390600 to GCOR-390602		Stipulated
320	NZ	9/29/04	NZ Letter to GCI re Spezyme Ethyl with Enclosures (allowed claims and published patent application)	NV-0001057		Stipulated

{W:\03776\6003018000\00876715.DOC *037766003018000* }

- 37 -